Related Links

Press Releases
Read

Analyst Coverage
Read

Submissions

As anyone in the life sciences industry well knows, time is money in the drug development market. Gartner estimates that bringing bringing a drug to market 20 days faster can net an additional $5M in a $100M market; $25M in a $500M market. Adoption of eCTD is forcing life sciences companies to rethink their submissions management strategy. One of the biggest tasks is prepping the documents involved in submissions, especially given the exponential nature of many of the regulatory docs needed. Further complicating matters, an eCTD can have thousands of life cycles, often confusing the regulatory group as to which document to replace and which version is correct. Good life cycle management reduces the risk of product recalls and liability suits - visibility that can avert damage to a company's reputation, brand, and market cap. A successful eCTD must capture all life cycle documents, including responses to questions, variations/amendments, renewals, annual reports, and other materials. We can help you with this critical process in a number of different ways starting with an assessment of your state of readiness. Ultimately the goal is to optimize your chances for success with your submission. Consulting services include:

All of these services can expedite your submissions process while increasing the knowledge base throughout your organization. Our regulatory advisors maintain RAC certifications as well as have extensive experience with global submissions -- both paper and electronic, having worked at some of the largest drug companies in the world optimizing submissions success. While many companies cannot keep up with the rapidly changing submissions guidelines and regulations, our advisors make it their business to maintain ongoing dialogue with the FDA to ensure our clients benefit from the latest interpretations of FDA guidelines and best practices.

Return to Advisory Overview